OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Outlook Therapeutics, Inc.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026
$0.49+0.00 (+0.98%)
Close on Oct 19, 2026
- Market cap
- $67.41M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.8170 (−62.37%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Outlook Therapeutics, Inc. reported revenue of $1.41M for fiscal 2025.
Revenue
$1.41M
FY2025
Operating income
-$55.64M
TTM Q3 2026
EPS, diluted
-$0.86
TTM Q3 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $67.41M
- P/E ratio
- –
- Price to sales
- 47.69
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $1.41M
- Net income
- -$61.12M
- EPS, diluted
- -$0.86
- Book value per share
- -$0.08
- Diluted shares
- 137M
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
-$2.28M
Operating income
-$55.64M
Net income
-$61.12M
EPS, diluted
-$0.86
Free cash flow
–
Reported periodTrailing twelve months